Small Cell Neuroendocrine Carcinoma

A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC)

PMID 28490518 · Sen et al., 2017 · Open in CIViC

In a phase II trial, patients with DLL3-expressing small cell lung carcinoma were treated with rovalpituzumab tesirine. Only patients with 1% or more tumor cells expressing DLL3 were enrolled. In this… (full text at CIViC)

PMID 31506387 · Morgensztern et al., 2019 · Open in CIViC

74 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma received at least one dose of rovalpituzumab tesirine in a phase 1 trial. 11 (18%) of 60 assessable patients … (full text at CIViC)

PMID 27932068 · Rudin et al., 2017 · Open in CIViC

In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells d… (full text at CIViC)

PMID 24893891 · Cross et al., 2014 · Open in CIViC

This report details 2 case studies in relapsed HER2 positive SCLC. In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had underg… (full text at CIViC)

PMID 25601188 · Kinehara et al., 2015 · Open in CIViC

Patient small-cell lung cancer cells with c-MET juxtamembrane mutations (R988C or T1010I) were shown to have increased tyrosine phosphorylated cellular proteins such as paxillin, a focal adhesion cyto… (full text at CIViC)

PMID 14559814 · Ma et al., 2003 · Open in CIViC

A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC)

PMID 28490518 · Sen et al., 2017 · Open in CIViC

A 51-year-old woman with an invasive small-cell cancer of the ureter showed a durable complete response at 3-years when treated with AZD7762 (an ATP-competitive checkpoint kinase inhibitor) and irinot… (full text at CIViC)

PMID 24934408 · Al-Ahmadie et al., 2014 · Open in CIViC

Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds rat… (full text at CIViC)

PMID 26802149 · Dowlati et al., 2016 · Open in CIViC

In a phase 2 basket trial, patients with small-cell lung carcinoma (SLC) who failed platinum-based chemotherapy and harbored RICTOR amplification were treated with mTOR 1/2 inhibitor vistusertib (AZD2… (full text at CIViC)

Open in CIViC

RICTOR amplification was observed in ca. 14% of 42 SCLC patients with panel sequencing results. 4 cell lines (2 with RICTOR CN gain, 2 without) were tested for the efficacy of mTOR pathway inhibitors.… (full text at CIViC)

PMID 27863413 · Sakre et al., 2017 · Open in CIViC

SLFN11 is a relevant predictive biomarker of sensitivity to PARP inhibitor monotherapy in SCLC as well as combinatorial therapy with TMZ.

PMID 27440269 · Lok et al., 2017 · Open in CIViC

In preclinical small cell lung carcinoma (SCLC) models with YES1 amplification or high expression, treatment with the YES1 inhibitor CH6953755 (30 mg/kg, q2d) or dasatinib (45 mg/kg daily) produced ma… (full text at CIViC)

PMID 35988891 · Redin et al., 2022 · Open in CIViC